Skip to content

LB Pharmaceuticals Inc

LBRX

CIK 0001691082

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$32.79M
+60.1% YoY Q1 May 2026
EPS Diluted (TTM)
−$55.56
+98.2% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$35.26M
Q1 May 2026
Cash
$320.68M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
28.68M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings